<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Biotransformation of flurbiprofen by Cunninghamella species</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Authors(s)</strong></td>
<td>Amadio, Jessica; Gordon, Katherine; Murphy, Cormac D.</td>
</tr>
<tr>
<td><strong>Publication date</strong></td>
<td>2010-09</td>
</tr>
<tr>
<td><strong>Publication information</strong></td>
<td>Applied and Environmental Microbiology, 76 (18): 6299-6303</td>
</tr>
<tr>
<td><strong>Publisher</strong></td>
<td>American Society for Microbiology</td>
</tr>
<tr>
<td><strong>Item record/more information</strong></td>
<td><a href="http://hdl.handle.net/10197/3780">http://hdl.handle.net/10197/3780</a></td>
</tr>
<tr>
<td><strong>Publisher's version (DOI)</strong></td>
<td>10.1128/AEM.01027-10</td>
</tr>
</tbody>
</table>
Biotransformation of flurbiprofen by *Cunninghamella* species

Jessica Amadio, Katherine Gordon and Cormac D. Murphy*

School of Biomolecular and Biomedical Science, Centre for Synthesis and Chemical Biology, Ardmore House, University College Dublin, Dublin 4, Ireland

*Corresponding author Fax: +353 (0)1 716 1183, Telephone: +353 (0)1 716 1311, email: Cormac.d.murphy@ucd.ie

Abstract

The biotransformation of the fluorinated anti-inflammatory drug flurbiprofen was investigated in *Cunninghamella* spp. Mono- and di-hydroxylated metabolites were detected using gas chromatography-mass spectrometry and fluorine-19 nuclear magnetic resonance spectroscopy, and the major metabolite 4’-hydroxyflurbiprofen was isolated by preparative HPLC. *C. elegans* DSM 1908 and *C. blakesleeana* DSM 1906 also produced a phase II (conjugated) metabolite, which was identified as the sulfated drug via deconjugation experiments.
One of the objectives of the recent European Union legislation governing the testing and evaluation of chemicals, REACH (Regulation, Evaluation, Authorisation and Restriction of Chemicals), is to further reduce the need for animals in the testing process. Some microorganisms, such as the zygomycete fungus Cunninghamella and actinomycetes bacteria, have been shown to metabolise xenobiotic compounds in an analogous fashion to mammals (3, 5, 11, 17). It was suggested over three decades ago that microorganisms had potential as models of mammalian metabolism (16), although there are concerns about their predictive value (8). Nevertheless, certain microorganisms can be applied to the generation of useful quantities of drug metabolic intermediates (13), which is more desirable than isolation of these compounds from dosed animals, and avoids the concerns often associated with chemical synthesis, such as the use of toxic reagents, and harsh reaction conditions.

Owing to the desirable physicochemical properties of the fluorine atom (small Van der Waals radius, electronegativity, strength of the carbon-fluorine bond) approximately 25% of drugs either currently on the market or in the pipeline are fluorinated (12). One such example is flurbiprofen [(RS)-2-(2-fluoro-4-biphenyl) propionic acid], which is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of inflammation caused by arthritis. In humans it is transformed to the phase I (oxidative) metabolites 4’-hydroxyflurbiprofen, 3’, 4’-dihydroxyflurbiprofen and 3’-hydroxy, 4’-methoxyflurbiprofen; glucuronide and sulfate conjugates (phase II metabolites) have also been detected (9, 15). In equine urine additional hydroxylated and methoxylated metabolites were detected (20). Tracy et al. (18) demonstrated that only one cytochrome P450 isoform (2C9) is involved in the oxidation of flurbiprofen, which makes the drug a potentially useful in vivo probe for this particular isoform. Despite the prevalence of fluorinated drugs, only a handful of investigations have been undertaken to determine the microbial biotransformation of these compounds (7, 21). Here we describe the biotransformation of flurbiprofen by
*Cunninghamella* species and the determination of the metabolites by nuclear magnetic resonance spectroscopy (\(^1\)H NMR and \(^{19}\)F NMR), GC-MS and HPLC.

Three species of *Cunninghamella* were selected for the biotransformation experiments: *C. elegans* (strains DSM 1908, DSM 8217, DSM 63299), *C. echinulata* DSM 1905 and *C. blakesleeana* DSM 1906. The fungi were grown on Sabouraud dextrose agar plates (Sigma) for 5 days at 26 °C before being homogenized in 100 ml of sterile saline solution. The homogenate (10 % v/v) was used to inoculate 50 ml of fresh Sabouraud dextrose broth in 250 ml Erlenmeyer flasks, which were incubated at 28 °C with shaking at 150 rpm. Following previously established procedures (2), 5 mg of flurbiprofen (Sigma) dissolved in dimethylformamide (20 µl) was added to the cultures after 72 h, and the incubation continued up to a further 120 h. Control experiments were conducted in either the absence of flurbiprofen or fungus. The cultures (supernatant and cells) were sonicated on ice (Sonicator U200S control, IKA Labortechnik) for 5 minutes at 50 % amplitude, with intervals of 30 seconds after each minute to prevent overheating. The sonicates were centrifuged and the supernatant extracted with 50 ml of ethyl acetate, and the extracts evaporated to dryness.

**Analysis of fluorinated metabolites.** *C. elegans* DSM 1908 is well known as a model of mammalian drug metabolism (10, 11) and analysis of the organically-extractable metabolites by \(^{19}\)F NMR spectroscopy using a Varian 400 MHz spectrometer revealed that flurbiprofen was completely degraded to one fluorometabolite over three days (Figure 1). The concentration of the metabolite was estimated at by using an internal standard (4-fluorobiphenyl) in \(^{19}\)F NMR analyses, and equated to 2 mg in the culture supernatant. No fluorinated products were detected in uninoculated control flasks.

The fluorometabolite was isolated by preparative reversed phase HPLC using a Varian Prostar HPLC system equipped with a Zorbax SB-C18 9.4 mm x 25 cm column (Agilent Technologies). Compounds were eluted with a gradient of acetonitrile/water (20-60
% acetonitrile) over 30 minutes at a flow rate of 3.5 ml/min. The main metabolite, which eluted at 19 minutes, was isolated and analysed by $^1$H and $^{19}$F NMR spectroscopy, and mass spectrometry. The spectrum obtained with $^1$H NMR analysis showed resonances at 1.56 ppm (CH$_3$, d), 3.78 ppm (CH, q), 6.9 ppm (C$_3$- and C$_5$-H, ddd), 7.14 ppm (C$_2$-H, ddd), 7.16 ppm (C$_6$-H, ddd), 7.37 ppm (C$_5$-H, ddd) 7.43 ppm (C$_2$- and C$_6$-H, ddd). There was no resonance for C$_4$-H indicating that the hydroxylation occurred in this position. The spectrum obtained by $^{19}$F NMR analysis showed one signal with a chemical shift of –117.85 ppm and splitting pattern identical to the flurbiprofen, (dd, $J= 11, 8$ Hz), indicating that there were no changes in the proximities of the fluorine atom. The metabolite was dried and further analysed by GC-MS as the per-trimethylsilylated derivative, which was formed by adding 50 µl N-methyl-N-(trimethyl-silyl) trifluoroacetamide (MSTFA) to the solid and heating at 100 ºC for 1 hour. The derivatized compound was diluted in ethyl acetate (1 ml) and an aliquot (1 µl) was injected onto a HP-1 column (12 m x 0.25 mm x 0.33 µm) and the oven temperature held at 120 ºC for 2 min then raised to 300 ºC at 10 ºC min$^{-1}$. The mass and fragmentation pattern of the metabolite, which had a retention time of 17.50 min, was composed of ions m/z 404 (M$^+$), 389 (M$^+$-CH$_3$), 287 (M$^+$-COOTMS), 268 (M$^+$-COOTMS, F), 253 (M$^+$-COOTMS, F, CH$_3$), and was identical to that described by (20) for 4′-hydroxyflurbiprofen.

Metabolic studies of flurbiprofen in human and different animal species reported the presence of several metabolites excreted in urine (15). The major metabolite was identified as 4′-hydroxyflurbiprofen and two minor ones as 3′,4′-dihydroxyflurbiprofen, 3′-hydroxy-4′-methoxyflurbiprofen. In the present study only one metabolite was detectable by $^{19}$F NMR, but since this technique is relatively insensitive additional analyses of the organically extractable metabolites were conducted by HPLC and GC-MS. HPLC analysis of time-course experiments up to 120 hours confirmed that flurbiprofen was completely degraded over three days to one polar metabolite with a retention time of 22.2 min (10-90% acetonitrile
over 30 min at 1 ml/min). GC-MS analyses of silylated organically soluble *C. elegans*
extracts revealed 4’-hydroxyflurbiprofen and other metabolites that could be tentatively
identified as hydroxylated and methoxylated flurbiprofen, based on their mass spectra (Table
1).

The microbial biotransformation of flurbiprofen was also investigated in selected
*Cunninghamella* strains previously shown to transform xenobiotics (4). GC-MS analysis of
the organically extractable metabolites, after derivatisation, demonstrated that they all
transformed the drug, to varying degrees, yielding the hydroxylated metabolites, and three of
the fungi generated hydroxylated methoxyflurbiprofen (Table 2). Using our methods, no
other organically soluble fluorometabolites were detected.

Phase II metabolism of flurbiprofen was studied since glucuronide and sulfate
flurbiprofen conjugates are reported to be important detoxification metabolites in mammals.
In humans, approximately 60-70% of flurbiprofen is excreted as conjugates (1), whereas less
than 30% of the flurbiprofen was reportedly conjugated in equine urine (20). Examination of
the aqueous extracts from *C. elegans* DSM 1908 by HPLC showed one peak at *t*<sub>R</sub> 17.8 min
that was not present in the organic extract analysis, and the <sup>19</sup>F NMR spectrum of aqueous
phase showed a signal at -119.2 ppm, which had a concentration of 0.1 mg/ml by comparison
with an internal standard of sodium fluoride. No fluorometabolites were detected in control
experiments. Enzymatic deconjugation was carried out by incubating the aqueous phase with
sulfatase (from *Helix pomatia* type H-1), β-glucoronidase (from *Escherichia coli*) and β-
glucosidase (from almonds) (Sigma) in phosphate buffer at 37°C for 12 h. The deconjugated
reaction products were extracted into ethyl acetate and analysed by GC-MS; 3’,4’-
dihydroxyflurbiprofen was detected after treatment with sulfatase, but no metabolites were
detected in extracts from deconjugation experiments with the other enzymes (Figure 2). The
other *Cunninghamella* species were examined for conjugated metabolites, and were only
observed in *C. blakesleeana*. The aqueous fraction from a culture of this strain that had been incubated with flurbiprofen was treated with the sequential addition of deconjugation enzymes (added in the order: sulfatase, β-glucoronidase and β-glucosidase) and the reactions monitored by $^{19}$F NMR spectroscopy between each addition (Figure 3), demonstrating that the sulfated metabolite was the only phase II compound present. Three resonances were initially observed, and metabolite I disappears after sulfatase treatment, with a concomitant increase in the height of metabolite III. Subsequent treatment with other deconjugative enzymes did not result in any further changes to the spectrum and subsequent HPLC analysis led to the conclusion that metabolites II and III are most likely 4′-hydroxy- and 3′,4′-dihydroxy-flurbiprofen, respectively.

The anti-inflammatory activity of profens, including flurbiprofen, are mainly ascribed to the active (S)-enantiomer (14). In human liver microsomes the (S)-enantiomer is transformed more rapidly than the (R) (19). In order to evaluate differences in the rate of degradation or metabolite formation between chiral and racemic flurbiprofen in fungi, biotransformation experiments were carried out using (R)-flurbiprofen. No difference in the formation of phase I and II metabolites was observed; the degradation was complete and comparable with the racemic flurbiprofen (data not shown). (R)-flurbiprofen was biotransformed predominantly to 4′-hydroxyflurbiprofen that was found to be identical to that produced by the racemate, based on $^{19}$F NMR and GC-MS analysis.

Previous studies showed that flurbiprofen has strong antifungal activity (6), so its effect on *C. elegans* DSM 1908 growth was investigated by incubating fungal spore suspension into Sabouraud dextrose liquid medium in 6-well plates (Sarstedt), with different concentrations of drug (0.1-5 mg/ml) added after 0, 6, 24 and 72 hours. Flurbiprofen completely inhibited germination starting at the lowest concentration administered at 0 and 6 hours; in the medium there was no presence of mature pellets of mycelium but only the
fragments of starting spore suspension. However, when flurbiprofen was added to cultures that were 24-72 h old, the fungal growth was not inhibited, and there was no difference in the biomass collected from culture flasks used in the biotransformation experiments that had been exposed to flurbiprofen and the control cultures to which no drug was added.

We have shown for the first time that flurbiprofen is converted by *Cunninghamella* spp. to a variety of phase I and phase II metabolites (Figure 4) present in several mammalian species including man. Among them, 4'-hydroxyflurbiprofen was confirmed to be the major product being converted by both mammalian and microbial systems. This similarity is remarkable considering that only one mammalian cytochrome P450 isoform can detoxify this drug. In fact, previous chemical inhibition studies confirmed that only P450 2C9 was involved in the 4'-hydroxylation of flurbiprofen in humans (18, 19). *C. elegans* DSM 1908 in particular would seem to be an appropriate microbial model of phase I metabolism in mammals since all the major metabolites are produced, in addition to new hydroxy- and hydroxy-methoxy isomers. The upscaling of the biotransformation may also have potential as a method of generating the metabolites as analytical standards, in particular 4'-hydroxyflurbiprofen.

**Acknowledgement**

The authors acknowledge financial assistance from the Environmental Protection Agency STRIVE Programme and thank Yannick Ortin for his support with the analysis of NMR spectra.

**References**


Table 1. GC-MS data for organic extracts of pertrimethylsilylated flurbiprofen and metabolites produced by *C. elegans* DSM 1908.

<table>
<thead>
<tr>
<th>Compound</th>
<th>( t_R ) (min)</th>
<th>( m/z ) of M(^+) (relative intensity)</th>
<th>( m/z ) of fragment ions (relative intensity)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flurbiprofen</td>
<td>12.85</td>
<td>316 (40)</td>
<td>301(54) 198(23) 180(100) 165(100) 73(100)</td>
</tr>
<tr>
<td>4’-OH-flurbiprofen(^{a,b})</td>
<td>16.15</td>
<td>404 (94)</td>
<td>389(43) 287(43) 268(72) 253(28) 73(100)</td>
</tr>
<tr>
<td>OH-flurbiprofen</td>
<td>16.64</td>
<td>404 (38)</td>
<td>389(26) 313(88) 285(100) 158(30) 73(60)</td>
</tr>
<tr>
<td>OH-flurbiprofen</td>
<td>16.75</td>
<td>404 (25)</td>
<td>389(13) 313(100) 246(17) 73(46)</td>
</tr>
<tr>
<td>OH-flurbiprofen</td>
<td>17.34</td>
<td>404 (6)</td>
<td>389(6) 298(40) 179(100) 73(57)</td>
</tr>
<tr>
<td>3’,4’-DiOH-flurbiprofen (^{a})</td>
<td>17.50</td>
<td>492 (55)</td>
<td>477(9) 375(16) 267(46) 73(100)</td>
</tr>
<tr>
<td>OH-MeO-flurbiprofen</td>
<td>13.63</td>
<td>434 (31)</td>
<td>419(7) 370(32) 314(80) 212(50) 73(100)</td>
</tr>
<tr>
<td>OH-MeO-flurbiprofen</td>
<td>14.68</td>
<td>434 (8)</td>
<td>419(3) 337(3) 129(55) 73(100)</td>
</tr>
</tbody>
</table>

\(^{a}\) The mass spectra of these compounds were identical to those reported by (18)

\(^{b}\) Approximately 80% of the total metabolites (by peak area) was 4’-OH-flurbiprofen.
Table 2. Qualitative analysis by GC-MS of biotransformation of flurbiprofen by *Cunninghamella* species.

<table>
<thead>
<tr>
<th>Compound</th>
<th><em>C. elegans</em> 1908</th>
<th><em>C. elegans</em> 8217</th>
<th><em>C. elegans</em> 63299</th>
<th><em>C. echinulata</em> 1905</th>
<th><em>C. blakesleeana</em> 1906</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flurbiprofen</td>
<td>_</td>
<td>+</td>
<td>+</td>
<td>_</td>
<td>_</td>
</tr>
<tr>
<td>4’-OH-flurbiprofen</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>3’-4’-DiOH-flurbiprofen</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>OH-MeO-flurbiprofen</td>
<td>+</td>
<td>_</td>
<td>_</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Figure legends

Fig. 1. Biotransformation of flurbiprofen and formation of its metabolite 4’-hydroxyflurbiprofen by *C. elegans* 1908 analyzed by $^{19}$F NMR at (a) 0, (b) 24 and (c) 72 hours.

Fig. 2. Gas chromatograms of metabolites present in *C. elegans* 1908 aqueous extract after treatment (a) without enzyme, (b) with sulfatase, (c) with β- glucoronidase and (d) β- glucosidase.

Fig. 3. $^{19}$F NMR analysis of *C. blakesleeana* 1906 aqueous extracts after treatment (a) without enzyme, (b) with sulfatase, (c) with β- glucoronidase and (d) β- glucosidase. The enzymes were added sequentially to the same extract.

Fig. 4. Principal biotransformation reactions of flurbiprofen in *C. elegans* 1908.
Figure 1
Fig 2
Figure 4

Flurbiprofen

CYT P450

4'-OH-flurbiprofen 3',4'-diOH-flurbiprofen OH-MeO-flurbiprofen

Sulfotransferase

OH-MeO-flurbiprofen 2',4'-diOH-flurbiprofen 4'-OH-flurbiprofen